Kellanova K is likely to register bottom-line growth when it reports fourth-quarter 2024 earnings on Feb. 6. Although the Zacks Consensus Estimate for quarterly earnings has moved down by a penny in the past 30 days to 82 cents per share, the projection indicates an increase of 5.1% from the year-ago quarter’s reported figure. The consensus mark for 2024 earnings is pegged at $3.75 per share, reflecting a 16.1% increase from the prior year’s reported figure. K has a trailing four-quarter earnings surprise of 10.9%, on average.

Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

The Zacks Consensus Estimate for Kellanova’s fourth-quarter revenues is pegged at $3.1 billion, which indicates a 2.6% decrease from the year-ago quarter. The consensus mark for 2024’s top line is pegged at $12.7 billion, which indicates a decline of 16.4% from the year-ago level.

Kellanova Price and Consensus

Kellanova price-consensus-chart | Kellanova Quote

Things to Know About K’s Upcoming Results

Kellanova has been benefiting from a strong focus on product innovation and an expansion strategy centered around key brands. The company is strategically implementing cost-saving measures to boost profitability and improve operational efficiency. In addition, Kellanova’s effective pricing strategies have been delivering positive results. These ongoing efforts are likely to have provided some relief in the fourth quarter. However, the company’s international presence exposes it to risks associated with unfavorable foreign currency fluctuations.

Earnings Whispers for K Stock

Our proven model predicts an earnings beat for Kellanova this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Kellanova carries a Zacks Rank #3 and has an Earnings ESP of +0.69%.

Other Stocks With the Favorable Combination

Here are other companies worth considering, as our model shows that these also have the right combination of elements to beat on earnings this reporting cycle.

$Aramark(ARMK-W)$ ARMK currently has an Earnings ESP of +5.53% and a Zacks Rank of 3. The company is likely to register growth in its top and bottom lines when it reports first-quarter fiscal 2025 numbers. The Zacks Consensus Estimate for Aramark’s quarterly revenues is pegged at $4.61 billion, which suggests an increase of 4.6% from the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Aramark’s quarterly earnings per share is pegged at 48 cents, indicating 17.1% growth from the year-ago period. ARMK has a trailing four-quarter earnings surprise of 8%, on average.

Kenvue Inc. KVUE currently has an Earnings ESP of +1.45% and a Zacks Rank of 3. The Zacks Consensus Estimate for quarterly revenues is pegged at $3.78 billion, which indicates growth of 2.9% from the figure reported in the prior-year quarter.

The Zacks Consensus Estimate for Kenvue’s fourth-quarter 2024 EPS is pegged at 25 cents, which implies a 19.4% decrease year over year. KVUE has a trailing four-quarter earnings surprise of 10.2%, on average.

Clorox CLX currently has an Earnings ESP of +0.78% and a Zacks Rank of 3. The company is likely to register a decline in its top and bottom lines when it reports second-quarter fiscal 2025 numbers. The Zacks Consensus Estimate for Clorox’s quarterly revenues is pegged at $1.63 billion, which suggests a decrease of 17.8% from the prior-year quarter.

The Zacks Consensus Estimate for Clorox’s quarterly earnings per share is pegged at $1.39, indicating a 35.7% decline from the year-ago period. CLX has a trailing four-quarter earnings surprise of 45.9%, on average.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Clorox Company (CLX) : Free Stock Analysis Report

Kellanova (K) : Free Stock Analysis Report

Aramark (ARMK) : Free Stock Analysis Report

Kenvue Inc. (KVUE) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research